High-level expression of ampC beta-lactamase due to insertion of nucleotides between -10 and -35 promoter sequences in Escherichia coli clinical isolates: cases not responsive to extended-spectrum-cephalosporin treatment.
Two Escherichia coli isolates were recovered from the blood of two cancer patients and were demonstrated to produce high levels of the AmpC beta-lactamase with isoelectric points of >9.0. The hypertranscription of ampC RNA was observed by Northern blot hybridization in both isolates. One isolate (isolate EC44) had a point mutation (G-->A at position -28) and insertion of thymidine between positions -20 and -19 of the ampC promoter gene (GenBank accession no. AE000487). The single nucleotide insertion of T between positions -19 and -20 created an optimal distance (17 bp) in the Pribnow box for ampC hyperproduction. The other isolate (isolate EC38) had two point mutations (G-->A at position -28 and C-->T at position +58) and a 2-base (GT) insertion between positions -14 and -15. Although the insertion of GT between positions -14 and -15 may create a new promoter next to the original promoter, cloning of the ampC region with truncated nucleotides of the original -35 region of EC38 failed to verify the hypothesis that a new promoter would be created by such a nucleotide insertion. Instead, multiple start sites for ampC transcription at -1, +1, +2, and +3 were observed in an S1 nuclease protection assay. These results suggest that the RNA polymerase is flexible in the selection of a start site in ampC hypertranscription. In conclusion, nucleotide insertions between the -35 and -10 ampC promoter sequences was the mechanism for the hyperproduction of AmpC beta-lactamase and resistance to oxyimino-cephalosporins. The failure of the two patients to respond to treatment with oxyimino-cephalosporins highlights the important role of such a resistance mechanism in the clinical setting.
Siu
L K
LK
Division of Clinical Research, National Health Research Institutes, National Taiwan University Hospital, Taipei, Taiwan. lksiu@mail.nhri.org.tw
Lu
Po-Liang
PL
Chen
J-Y
JY
Lin
F M
FM
Chang
Shan-Chwen
SC
D001426:Bacterial Proteins; D001483:Base Sequence; D018550:Cephalosporin Resistance; D002511:Cephalosporins / Q000627:therapeutic use*; D003001:Cloning, Molecular; D016172:DNA Fingerprinting; D004926:Escherichia coli / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics*; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000382:microbiology; D015964:Gene Expression Regulation, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D010957:Plasmids; D011401:Promoter Regions, Genetic / Q000235:genetics; D012336:RNA, Ribosomal, 16S / Q000032:analysis; D015719:Single-Strand Specific DNA and RNA Endonucleases; D001618:beta-Lactamases / Q000235:genetics* / Q000378:metabolism
D001426:Bacterial Proteins; D002511:Cephalosporins; D012336:RNA, Ribosomal, 16S; D015719:Single-Strand Specific DNA and RNA Endonucleases; C048795:AmpC beta-lactamases; D001618:beta-Lactamases